These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 28427554)

  • 1. Clinical and hemodynamic improvements after adding ambrisentan to background PDE5i therapy in patients with pulmonary arterial hypertension exhibiting a suboptimal therapeutic response (ATHENA-1).
    Shapiro S; Torres F; Feldman J; Keogh A; Allard M; Blair C; Gillies H; Tislow J; Oudiz RJ
    Respir Med; 2017 May; 126():84-92. PubMed ID: 28427554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of efficacy, safety and tolerability of Ambrisentan in Chinese adults with pulmonary arterial hypertension: a prospective open label cohort study.
    Huo Y; Jing ZC; Zeng XF; Liu JM; Yu ZX; Zhang GC; Li Y; Wang Y; Ji QS; Zhu P; Wu BX; Zheng Y; Wang PP; Li J
    BMC Cardiovasc Disord; 2016 Oct; 16(1):201. PubMed ID: 27770771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and tolerability of combination therapy with ambrisentan and tadalafil for the treatment of pulmonary arterial hypertension in children: Real-world experience.
    Issapour A; Frank B; Crook S; Hite MD; Dorn ML; Rosenzweig EB; Ivy DD; Krishnan US
    Pediatr Pulmonol; 2022 Mar; 57(3):724-733. PubMed ID: 34921523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of ambrisentan in Chinese patients with connective tissue disease-pulmonary arterial hypertension: a post-hoc analysis.
    Li M; Jing ZC; Li Y; Huo Y; Yu Z; Zhang G; Zhu P; Liu J; Ji Q; Wu B; Zhong J; Wang P; Zhu W; Zeng X
    BMC Cardiovasc Disord; 2020 Jul; 20(1):339. PubMed ID: 32680480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized study of adding tadalafil to existing ambrisentan in pulmonary arterial hypertension.
    Zhuang Y; Jiang B; Gao H; Zhao W
    Hypertens Res; 2014 Jun; 37(6):507-12. PubMed ID: 24646647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ambrisentan: a review of its use in pulmonary arterial hypertension.
    Rivera-Lebron BN; Risbano MG
    Ther Adv Respir Dis; 2017 Jun; 11(6):233-244. PubMed ID: 28425346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) - A subgroup analysis of the ARIES-E clinical trial.
    Fischer A; Denton CP; Matucci-Cerinic M; Gillies H; Blair C; Tislow J; Nathan SD
    Respir Med; 2016 Aug; 117():254-63. PubMed ID: 27492539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ambrisentan for the treatment of adults with pulmonary arterial hypertension: a review.
    Peacock AJ; Zamboni W; Vizza CD
    Curr Med Res Opin; 2015; 31(9):1793-807. PubMed ID: 26196225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.
    Galiè N; Barberà JA; Frost AE; Ghofrani HA; Hoeper MM; McLaughlin VV; Peacock AJ; Simonneau G; Vachiery JL; Grünig E; Oudiz RJ; Vonk-Noordegraaf A; White RJ; Blair C; Gillies H; Miller KL; Harris JH; Langley J; Rubin LJ;
    N Engl J Med; 2015 Aug; 373(9):834-44. PubMed ID: 26308684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial.
    Coghlan JG; Galiè N; Barberà JA; Frost AE; Ghofrani HA; Hoeper MM; Kuwana M; McLaughlin VV; Peacock AJ; Simonneau G; Vachiéry JL; Blair C; Gillies H; Miller KL; Harris JHN; Langley J; Rubin LJ;
    Ann Rheum Dis; 2017 Jul; 76(7):1219-1227. PubMed ID: 28039187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial combination therapy with ambrisentan and tadalafil and mortality in patients with pulmonary arterial hypertension: a secondary analysis of the results from the randomised, controlled AMBITION study.
    Hoeper MM; McLaughlin VV; Barberá JA; Frost AE; Ghofrani HA; Peacock AJ; Simonneau G; Rosenkranz S; Oudiz RJ; White RJ; Miller KL; Langley J; Harris JHN; Blair C; Rubin LJ; Vachiery JL
    Lancet Respir Med; 2016 Nov; 4(11):894-901. PubMed ID: 27745818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of newly diagnosed sarcoid-associated pulmonary hypertension with ambrisentan and tadalafil combination therapy.
    Abston E; Hon S; Lawrence R; Berman J; Govender P; Farber HW
    Sarcoidosis Vasc Diffuse Lung Dis; 2020; 37(2):234-238. PubMed ID: 33093789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety and tolerability of ambrisentan treatment for pediatric patients with pulmonary arterial hypertension: An open-label extension study.
    Ivy D; Beghetti M; Juaneda-Simian E; Ravindranath R; Lukas MA; Machlitt-Northen S; Scott N; Narita J; Berger RMF
    Eur J Pediatr; 2024 May; 183(5):2141-2153. PubMed ID: 38366267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.
    Galiè N; Olschewski H; Oudiz RJ; Torres F; Frost A; Ghofrani HA; Badesch DB; McGoon MD; McLaughlin VV; Roecker EB; Gerber MJ; Dufton C; Wiens BL; Rubin LJ;
    Circulation; 2008 Jun; 117(23):3010-9. PubMed ID: 18506008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ambrisentan therapy for pulmonary arterial hypertension.
    Galié N; Badesch D; Oudiz R; Simonneau G; McGoon MD; Keogh AM; Frost AE; Zwicke D; Naeije R; Shapiro S; Olschewski H; Rubin LJ
    J Am Coll Cardiol; 2005 Aug; 46(3):529-35. PubMed ID: 16053970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An update on the use of ambrisentan in pulmonary arterial hypertension.
    D'Alto M
    Ther Adv Respir Dis; 2012 Dec; 6(6):331-43. PubMed ID: 22933513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension.
    Hassoun PM; Zamanian RT; Damico R; Lechtzin N; Khair R; Kolb TM; Tedford RJ; Hulme OL; Housten T; Pisanello C; Sato T; Pullins EH; Corona-Villalobos CP; Zimmerman SL; Gashouta MA; Minai OA; Torres F; Girgis RE; Chin K; Mathai SC
    Am J Respir Crit Care Med; 2015 Nov; 192(9):1102-10. PubMed ID: 26360334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension.
    Oudiz RJ; Galiè N; Olschewski H; Torres F; Frost A; Ghofrani HA; Badesch DB; McGoon MD; McLaughlin VV; Roecker EB; Harrison BC; Despain D; Dufton C; Rubin LJ;
    J Am Coll Cardiol; 2009 Nov; 54(21):1971-81. PubMed ID: 19909879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study.
    Kimura M; Tamura Y; Takei M; Yamamoto T; Ono T; Fujita J; Kataoka M; Kuwana M; Satoh T; Fukuda K
    BMC Pulm Med; 2015 May; 15():62. PubMed ID: 25971443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ambrisentan, an endothelin receptor type A-selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension.
    Kingman M; Ruggiero R; Torres F
    Expert Opin Pharmacother; 2009 Aug; 10(11):1847-58. PubMed ID: 19601701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.